Low C4 levels in Type 1 (insulin-dependent) diabetes HLA phenotype and secondary failure to oral hypoglycaemic agents Dear Sir, We read with interest the paper of Charlesworth et al. [1] on the complement system in Type 1 (insulin-dependent) diabetes. These authors concluded that significant C4 reduction occurred in the Type 1 patients independently of null alleles at the C4 genetic loci. This conclusion was based on a comparison between C4 concentrations in a group of randomly selected control subjects and a group of diabetic patients "without detectable null alleles". The method of null allele detection used was two-dimensional immunoelectrophoresis. This produces two peaks of immunoprecipitation the heights of which are proportional to the concentrations of the C4A and C4B proteins. Peaks of equal heights may indicate a complete absence of null alleles, but this finding is also compatible with the double heterozygous null genotype (one A null allele and one B null allele) [2] . The distinction between these alternative interpretations can sometimes be made on the basis of extensive family studies or by Southern blot analysis (A null is associated with a specific restriction fragment length polymorphism [3] ). No indication is given in the paper that such studies were performed. Both A null and B null are found as components of extended haplotypes associated with Type 1 diabetes [4] , and therefore it is fikely that the group designated "no null alleles" contains subjects with the double heterozygous null genotype.
In our own data 60% of the Type I diabetic patients with low C4 concentrations (< 0.23 g/l) were homozygous null at the A or the B locus [5l. It is likely that a proportion of the remaining 40% also had null alleles. This suggests that most if not all the low C4 values in our diabetic patients are genetic in origin. We conclude that the differences in C4 concentration between the group "without detectable null alleles" and th e control subject group found by Charlesworth et al. may be accounted for by an increased frequency of null alleles in the Type 1 diabetic patients. [1] claim that insulin response to glucagon in patients with Type 2 (non-insulin-dependent) diabetes is associated with some HLA antigens (reduced in patients with B8/B15 and DR3/DR4, enhanced in patients with DR5 and DRWS), and that patients requiring insulin treatment, because of secondary failure to oral hypoglycaemic agents (OHA), show reduced insulin release and a HLA phenotype characteristic of Type 1 (insulin-dependent) diabetes, probably a slowly-progressing Type 1 diabetes. A definition of secondary failure to OHA is still lacking: in our view the term of secondary failure should be restricted to those patients who, despite full compliance to diet and therapy, become insensitive to OHA and require insulin to control glucose metabolism. We have recently shown Patients on OHA and on insulin were matched for body mass, duration of disease (+2years) and age at diagnosis (+4years). Each patient was evaluated for: HLA phenotype (locus A defined by 135 monospecific antisera, locus B by 27, locus C by 8, locus DR by 12 monospecific antisera) [3, 4] ; C-peptide release at fasting, 6 rain after intravenous glucagon 1 mg, and 2 h after lunch [5, 6] ; and islet cell antibodies (ICA) [7, 81. The frequency of HLA phenotype was compared to that of 43 Type I diabetic patients (age 29.0+_2.0; age at onset 22.6+_2.2; duration of diabetes 9.7 + 1.5) and of 905 blood donors [91 at the Istituto Nazionale per lo Studio e la Cura dei Tumor for loci A, B, and C, and of 455 healthy Italian subjects for locus DR [10] .
Antisera for HLA typing were provided by Biotest Serum Institute (Frankfurt, FRG), Fresenius AG (Bad Homburg v. d., FRG) Tissue Typing Laboratory (Los Angeles, Calif, USA) and other Italian and foreign tissue typing laboratories. Reagents for C-peptide radioimmunoassay were supplied by Byk-Mallinkrodt (Dietzenbach, FRG); the assay had the following characteristics: sensitivity 0.1 ng/ml; recovery 98% at I ng/ml and 115% at 15 ng/ml; intra-assay and interassay coefficients of variation 6.0% and 2.5% respectively. X z was used for comparisons.
A total of 7 (9.4%) patients with Type 2 diabetes (4 on OHA, 3 on insulin) were ICA positive. HLA B13, CW4 and DR7 were more frequent while B7 was less frequent among Type 2 diabetic patients than among control subjects; DR3 and DR4 were more frequent, A1 and DR5 were less frequent among Type 1 diabetic patients than among control subjects; DR3 and DR4 were more frequent and DR5 was less frequent among Type i than among Type 2 diabetic patients (Table 1) . When patients with Type 2 diabetes were divided according to the kind of treatment (OHA vs insulin) or according to the presence of ICA, no differences of HLA phenotype appeared.
In the whole group of patients with Type 2 diabetes, C-peptide release was 2.3 +0.2 ng/ml at fasting; 3.5 + 0.3 ng/ml after intravenous glucagon, and 4.4 + 0.3 ng/ml post-prandial; no differences appeared according to HLA phenotype, even for patients with DR3 or DR4 vs patients without DR3 or DR4 (2.7+_0.5 vs 2.0+_0.2 ng/ml at fasting; 4.0+_0.6 vs 3.4+0.3ng/ml after intravenous glucagon; 4.8 + 0.8 vs 4.3 _ 0.4 ng/ml post-prandially).
By X 2 for heterogeneity test [11] for all loci, a significant difference appears between our blood donors and the subjects studied by Groop et al. (XZ=807, 35 dfs, p<0.00001); in addition, only frequencies of DR4 and DR5 are similar in Scandinavian and Finnish healthy control subjects, while frequencies of DR3 and DR7 are closer in Italian and in Scandinavian healthly control subjects [4] .
We conclude that in our patients, secondary failure to OHA is not associated with any HLA antigen. The findings by Groop et al. [1] apply only to the Finnish population and cannot be extrapolated to other ethnic groups. In our view, patients with secondary failure to OHA represent a sub-group of patients with Type 2 diabetes with a quick exhaustion of B-ceU function; this process does not seem to be mediated immunologic or genetic factors.
Yours sincerely, A. E. Pontiroli, A. Calderara, G. Pozza 
Insulin immunology in mono-component insulin treated patients
Dear Sir, I read with appreciation and interest a review by Drell and Notkins [1] of immunological abnormalities in Type I (insulin-dependent) diabetes. The authors find an incidence in the literature of 40%-50% blastogenesis to insulin in Type 1 diabetes and also an absence of response of the resting lymphocyte to insulin.
Our published data [2] reported non-responsiveness to monocomponent insulins in 29 diabetic patients regardless of therapeutic insulin used, compared to control subjects; and in 12 mono-component insulin treated patients using B component of insulin as antigen there was no significant difference, but there was a significant stimulation (transformation index 1.8, p < 0.01) observed in the non monocomponent treated patients. We concluded that insulin per se was non antigenic and that the pro-insulin contained in the non-monocomponent insulin preparations had presensitised the lymphocytes of those diabetic patients.
An observation in our studies [2] not referred to in this review [1] , is the stimulatory effect of zinc on blastogenesis, bearing in mind the zinc content of insulin. Our studies did not observe any difference in transformation comparing zinc with insulins in diabetic patients, but in one group of control subjects we noted a very definite stimulatory effect of zinc compared with B component (zinc transformation index 1.52, n=6; B component transformation index 1.01, n=6; 0.02 <p < 0.05). We believe that attention must be paid to the previous insulin therapy of patients and to the constituents of the stimu-
